Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syros Pharmaceuticals Inc SYRS

Healthcare Biotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARa), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in... see more

Recent & Breaking News (NDAQ:SYRS)

Syros Reports Second Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire August 7, 2018

Syros to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

Business Wire July 31, 2018

Investor Expectations to Drive Momentum within ShotSpotter, Kohl's, Cheniere Energy Partners LP, Palo Alto Networks, Syros Pharmaceuticals, and Ryman Hospitality Properties — Discovering Underlying Factors of Influence

GlobeNewswire July 26, 2018

Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018

Business Wire July 10, 2018

Syros Announces Appointment of Michael W. Bonney to Its Board of Directors

Business Wire June 14, 2018

Syros to Present at Upcoming Investor Conferences

Business Wire May 30, 2018

Syros to Present on Design of Ongoing Phase 1 Clinical Trial of SY-1365 at Upcoming ASCO Annual Meeting

Business Wire May 16, 2018

Syros Reports First Quarter 2018 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Business Wire May 10, 2018

Syros to Report First Quarter 2018 Financial Results on Thursday, May 10, 2018

Business Wire May 3, 2018

Syros Announces New Preclinical Data on SY-1365 Showing Potent Anti-Tumor Activity in Multiple Models of Heavily Pretreated Ovarian Cancer

Business Wire April 16, 2018

Syros to Present New Preclinical Data on SY-1365 in Ovarian Cancer at Upcoming AACR Annual Meeting

Business Wire March 14, 2018

Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones

Business Wire March 12, 2018

Syros Announces Appointment of Joseph J. Ferra as Chief Financial Officer

Business Wire March 12, 2018

Syros to Present at Upcoming Investor Conferences

Business Wire March 5, 2018

Syros to Present at Leerink Partners 7th Annual Global Healthcare Conference

Business Wire February 8, 2018

Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

Business Wire February 7, 2018

Syros Announces Pricing of $40 Million Public Offering of Common Stock

Business Wire January 30, 2018

Syros Announces Proposed Offering of Common Stock

Business Wire January 30, 2018

Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARα Agonist

Business Wire January 22, 2018

Syros Announces 2018 Strategic Priorities and Expected Milestones

Business Wire January 8, 2018